Rheumatoid Arthritis Drugs Market Trends, Leading Companies, Company Revenue / Sales Performance, Procedure Volume, Healthcare Spending, Technology Adoption, Reimbursement Analysis, Competitive Landscape, and Growth Outlook

Revenue, 2025

USD 64.35 billion

Forecast Year, 2035

USD 76.83 billion

CAGR, 2026 - 2035

1.79%

Report Coverage

Global

What is the Rheumatoid Arthritis Drugs Market Size?

The global rheumatoid arthritis drugs market size was calculated at USD 64.35 billion in 2025 and is predicted to reach around USD 76.83 billion by 2035, expanding at a CAGR of 1.79% from 2026 to 2035.

Rheumatoid Arthritis Drugs Market Key Takeaways

• North America led the global market with the highest market share of 58.25% in 2025.
• By drug type, the disease-modifying anti-rheumatic drugs (DMARDs) segment dominated the market with 64.10% in 2025.
• By drug type, the DMARDs (esp. Biologics & Targeted Synthetics) segment is expected to grow at the highest CAGR of 7.80% in 2025.
• By route of administration, the oral segment held a 57.30% market share in 2025.
• By route of administration, the parentral segment is expected to grow at the highest CAGR of 6.90% in 2025.
• By Distribution Channel, the hospital pharmacies segment led the market by holding 41.60% in 2025.
  By Distribution Channel, the online pharmacies segment is expected to grow at the highest CAGR of 8.30% in 2025.
• By patient type, the adult segment held a 94.20% market share in 2025.
• By patient type, the pediatric segment is expected to grow at the highest CAGR of 6.10% in 2025.
• By mode of purchase, the prescription-based segment dominated the market with 88.50% in 2025.
• By mode of purchase, the over-the-counter segment is expected to grow at the highest CAGR of 5.70% share in 2025.

Rheumatoid Arthritis Drugs Market Growth Factors

One of the significant factors driving the growth of global rheumatoid arthritis drugs market is rising prevalence of rheumatoid arthritis. The worldwide prevalence of rheumatoid arthritis, based on a systematic review was predicted to be 0.46%, as per the study published in November 2020. As a result, more rheumatoid arthritis drugs will be adopted, propelling the rheumatoid arthritis drugs market forward.

The global rheumatoid arthritis drugs market is expected to benefit significantly from increased launches of innovative biologics and expanding generic medication penetration. In Japan, for example, Eli Lilly and Company's release of Olumiant in 2017 is expected to stimulate revenue growth. Likewise, AbbVie's Upadacitinib, a JAK1-selective inhibitor, is expected to be approved in 2019. Due to the favorable reimbursement landscape, recently authorized biologics like Kevzara and Xeljanz are expected to have a high market penetration.

Another factor driving the growth of global rheumatoid arthritis drugs market is growing patient awareness regarding rheumatoid arthritis disorders. In the U.S., 52.2 million persons affected with rheumatoid arthritis in 2013. Due to inadequate therapeutic benefits, the majority of patients diagnosed with Disease Modifying Antirheumatic Drugs remain dissatisfied. A combination of Disease Modifying Antirheumatic Drugs and biologics is more likely to provide therapeutic advantages for this patient population. Thus, there is a movement in the rheumatoid arthritis drugs market toward combination medicines that deliver better benefits for patients.

The growth of global rheumatoid arthritis drugs market is also being driven by growing constant efforts for development of rheumatoid arthritis drugs and medications by government agencies. The government is also taking assistance of major market players for development and growth of global rheumatoid arthritis drugs market. In addition, government agencies are also investing in innovative and latest technologies for the development of rheumatoid arthritis drugs in the global market. As a result, all of these aforementioned factors are boosting the growth of global rheumatoid arthritis drugs market.

Market Scope

Segment Insights

Molecule Type Insights

The biologics segment accounted revenue share of around 61% in 2025. The biopharmaceutical production capacity is expected to increase as manufacturing capabilities are improved. In the synthesis and processing of biopharmaceuticals, single use methods are also being used. In addition, researchers are looking towards more productive species and expression methods. Revenue generation is expected to be fueled by the development of reagents and cell lines that improve biological products output.

The biosimilars segment is fastest growing segment over the forecast period. The segment's expansion is aided by increased availability, low price, and favorable results. Their demand is considerable in emerging nations; however, because to the introduction of newer, more effective products, they are progressively gaining momentum in industrialized nations. Glenmark Pharmaceuticals released a biosimilar for Humira in India in January 2018. In upcoming years, new biosimilars are expected to cause a dramatic shift in prescription patterns.

Sales Channel Insights

The over-the-counter drugs (OTC) segment dominated the rheumatoid arthritis drugs market in 2025. The prescription drugs include a wide range of vaccinations and therapies for the treatment and diagnostics of rheumatoid arthritis. Many market companies are conducting clinical studies for the development of novel treatments for a variety of conditions, but the prescription drug landscape has changed dramatically as a result of the rising availability of generic medicines.

The prescription drugs segment is expected to witness strong growth from 2024 to 2033. The over-the-counter drugs are pharmaceuticals that are regarded safe to purchase without a prescription from a medical expert. These drugs are sold lawfully without a prescription in medical stores and hospital pharmacies.

Drug Type Insights

The disease-modifying anti-rheumatic drugs (DMARDs) segment dominated the market with 64.10% in 2025. The dominance of the segment can be attributed to the increasing prevalence of rheumatic diseases across the globe. Disease-modifying antirheumatic drugs are a class of drugs used to treat inflammatory arthritides such as psoriatic arthritis and rheumatoid arthritis.

The DMARDs (esp. Biologics & Targeted Synthetics) segment is expected to grow at the highest CAGR of 7.80% in 2024. The biopharmaceutical production capacity is expected to increase as manufacturing capabilities are improved. In the synthesis and processing of biopharmaceuticals, single-use methods are also being used. In addition, researchers are looking towards more productive species and expression methods. Revenue generation is expected to be fueled by the development of reagents and cell lines that improve the output of biological products.

Route of Administration Insights

The oral segment held a 57.30% market share in 2025. The dominance of the segment can be linked to the rising incidence of RA and the surge in geriatric populations. Also, Oral medications provide a sophisticated and pain-free way for patients to control their RA, which makes them a favoured choice for many, impacting segment growth soon.

The parentral segment is expected to grow at the highest CAGR of 6.90% in 2024. The growth of the segment can be driven by growing demand for effective treatments along with innovations in biosimilars and biologics. Moreover, parenteral administration, especially intravenous and subcutaneous routes, provides benefits such as precise dosage control and rapid onset of action.

Distribution Channel Insights

The hospital pharmacies segment led the market by holding 41.60% in 2025. The dominance of the segment can be credited to the growing use of disease-modifying antirheumatic drugs (DMARDs) and biologics and the rising incidence of RA. Furthermore, the geriatric population is more prone to RA, and raised awareness regarding early diagnosis and treatment is also impacting segment growth.

The online pharmacies segment is expected to grow at the highest CAGR of 8.30% in 2024. The growth of the segment is owing to the surge in online pharmacies offering these drugs along with the favorable reimbursement policies for biologics. The trend towards customised medicine, with catered treatment approaches for individual patients, is contributing to segment expansion further.

Patient Type Insights

The adult segment held a 94.20% market share in 2025. The dominance of the segment can be attributed to the innovations in drug development, the surge in prevalence of rheumatoid arthritis, and growing awareness about the disease. Also, innovations in diagnostic tools are allowing for more precise diagnosis of RA, which leads to better patient outcomes.

The pediatric segment is expected to grow at the highest CAGR of 6.10% in 2024. The growth of the segment can be credited to the growing incidence of juvenile idiopathic arthritis (JIA) and the development of targeted therapies. Furthermore, favorable regulatory policies such as Pediatric Investigational New Drug (PIP) are encouraging pharmaceutical companies to create test drugs for pediatric RA.

Mode of Purchase Insights

The prescription-based segment dominated the market with 88.50% in 2025. The prescription drugs include a wide range of vaccinations and therapies for the treatment and diagnosis of rheumatoid arthritis. Many market companies are conducting clinical studies for the development of novel treatments for a variety of conditions, but the prescription drug landscape has changed dramatically as a result of the rising availability of generic medicines.

The over-the-counter segment is expected to grow at the highest CAGR of 5.70% share in 2024. The over-the-counter drugs are pharmaceuticals that are regarded as safe to purchase without a prescription from a medical expert. These drugs are sold lawfully without a prescription in medical stores and hospital pharmacies.

Regional Insights

U.S. Rheumatoid Arthritis Drugs Market Size and Growth 2026 to 2035

The U.S. rheumatoid arthritis drugs market size was evaluated at USD 26.51 billion in 2025 and is projected to be worth around USD 32.9 billion by 2035, growing at a CAGR of 2.18% from 2026 to 2035.

North America region has garnered 58.25% revenue share in 2025. As per the Centers for Disease Control and Prevention, nearly one in every four individuals in the U.S. or 58.5 million people, has arthritis. Furthermore, the government of Canada estimates that 374,000 of Canadians aged 16 and up have rheumatoid arthritis. Due to this disease's widespread prevalence, more medicines will be used, resulting in rheumatoid arthritis drugs market expansion in the North America region. In addition, easy approvals by government agencies on pharmaceuticals and drugs are also driving the growth of North America rheumatoid arthritis drugs market.

What Is Driving the Growth of the Rheumatoid Arthritis Drugs Market in Asia Pacific?

Asia-Pacific, on the other hand, is expected to develop at the fastest rate during the forecast period. The Asia-Pacific rheumatoid arthritis drugs market's expansion is being fueled by increased awareness of disease remission therapy, high public and private healthcare expenditure, and rising rheumatoid arthritis incidences. Furthermore, revenue growth in Asia-Pacific region is expected to be aided by simple access to high quality healthcare, a robust clinical product portfolio, advantageous reimbursement rules, and the approval of innovative pharmaceuticals. The acceptance of urban lifestyle is resulting in an increase in the number of patients in the region. This, together with rising healthcare spending, is likely to drive Asia-Pacific rheumatoid arthritis drugs market forward. The favorable regulatory rules for biosimilars are expected to improve demand for medicines are driving the overall growth of the market.

Competitive Landscape

The rheumatoid arthritis drugs market is aligned with modern medical needs and biosolutions. The range of biosimilars production is followed by medication management transitions. The adaptability of fine-modest drugs in the medical spectrum promotes the market intention to the core. The targeted synthetic therapies are the reason for this drug's expansion. The market leaders such as AbbVie Inc., Sun Pharma, Lupin, Pfizer Inc. and Sandoz, Amgen and Samsung Bioepis are the foundation of the market growth.

Company Profiles

AbbVie Inc.

• HQ: North Chicago, Illinois, USA
  
• Founded: 2013
  
• Ownership: Biopharmaceutical Company
  
• Business Overview: AbbVie's business focuses on oncology, immunology and research and development. The funding in research and development is a huge contribution to AI and other robust technologies by the company.
  
• Products: Imbruvica, Elahere, and other treatments.
  
• Geographic Presence: The company's business is across 70 countries, and product sales cover 175 countries across five regions.
  
• Revenue: The 2026 Q1 revenue was $15.002 billion, and by Q2 it will increase by 10.2%.
  
• Recent Development: In October 2025, AbbVie introduced blockbuster Rinvoq and Skyrizi drugs that gained traction in drug sales, giving tough competition to Humira. The new drugs are a boon to the arthritis portfolio.
  
• Key Strategies: The company's strategy is to enhance the drug status to contribute the most to the market and the whole medical sector.

Sun Pharma

• HQ: Mumbai, India
  
• Founded: 1983
  
• Ownership: Pharmaceutical Company and Specialty Generic Pharmaceutical Firm
  
• Business Overview: Sun's business is rooted in its manufacturing status and international expansion. The valuable spending on research and development introduces a excellence teamof scientist in favor of drug discovery and development.
  
• Products: APIs, capsules, tablets, creams, liquids, OTC products, etc.
  
• Geographic Presence: The range of 2,000 branded generic and basic generic formulas covers 100 countries and 40 manufacturing facilities.
  
• Revenue: Sun's turnover is US$6.2 billion to US$ 6.58 billion billion
  
• Key Strategies: The company's strategy is to modernize the manufacturing sites and dig into the drug needs to meet patient outcome needs.

Lupin

• HQ: Mumbai, India
  
• Founded: 1968
  
• Ownership: Pharmaceutical Company
  
• Business Overview: Lupin's business aims on specialties, APIs, biotechnology products and drugs that contribute to the medical sector and help the company to earn profit from its promising drug sales. It also focuses on the conditions to introduce drug expertise in real time.
  
• Products: Tiotropium bromide inhalation powder, linagliptin, etc.
  
• Geographic Presence: The company operates across 11 countries and has distribution covering 100 markets.
  
• Revenue: Lupin's revenue from its operations keeps on increasing by 33.3%, which is ₹8,217 crore as predicted for Q1 FY2027.
  
• Recent Development: In February 2026, Yoshindo and Lupin's JV-YL biologics proudly announced the success of its Phase 3 study for etanercept biosimilar in rheumatoid arthritis. This is a milestone for the market as well.
  
• Key Strategies: The company's motive is to complete the clinical targets and introduce a range of drugs to accelerate the company's drug portfolio reach in the healthcare industry and medication management.

Pfizer Inc.

• HQ: New York City
  
• Founded: 1849
  
• Ownership: Multinational Biopharmaceutical and Biotechnology Corporation
  
• Business Overview: Pfizer's smart and kind business is to upgrade science in the new modern healthcare with its vaccines and drugs. The medication profile of the company is paving the way for more business in healthcare.
  
• Products: Lipitor, Xanax, Vyndawel, Prevnar, etc.
  
• Geographic Presence: The company runs its product distribution chain across 200 countries and territories.
  
• Revenue: The company's 2025 annual revenue was $62.58 billion and is expected to expand during the forecast period.
  
• Recent Development: In December 2025, Pfizer and Adaptive entered into a deal of $890 million for the research of rheumatoid arthritis research to bolster the study of the drug formula that will lead to progress in development, sales and research as well.
  
• Key Strategies: Pfizer's strategy is to build a next-generation medication formula to strengthen the vaccination delivery systems. Innovation is a key power for the company's success.

Sandoz, Amgen and Samsung Bioepis

• HQ: Sandoz – Basel, Switzerland, Amgen – Thousand Oaks, California and Samsung – Incheon, South Korea.
  
• Founded: Sandoz – 1886, Amgen – 1980 and Samsung – 2012.
  
• Ownership: Biopharmaceutical Industry (Collaboration-based company)
  
• Business Overview: The companies are in merger activism to share expertise for bolstering drug formulas and expand its engagement in healthcare. The blockbusters of the companies and shared innovation accelerate the overall business.
  
• Products: Hadlima, Ontruzant, Prolia, Xgeva, etc.
  
• Geographic Presence: The companies' reach occupies 100-plus countries, with Samsung leading in all regions due to the alliance.
  
• Revenue: The company's revenue in 2025 was $35.148 billion, and in 2026 Q1 it earned $8.218 billion in profit.
  
• Key Strategies: The motive is to expand the drug portfolio and build a strong position in the drug discovery and development space.
  

Rheumatoid Arthritis Drugs Market Companies

• AbbVie
• Boehringer Ingelheim GmbH
• Novartis AG
• Regeneron Pharmaceuticals, Inc.
• Pfizer, Inc.
• Bristol-Myers Squibb Company
• F. Hoffmann-La Roche Ltd.
• UCB S.A.
• Johnson & Johnson Services, Inc.
• Amgen, Inc.

Recent Developments

The global rheumatoid arthritis drugs industry is dominated by biopharmaceutical manufacturers. Due to the price sensitive population in emerging nations, only a few market players provide both generic and branded pharmaceuticals. To strengthen their market position, companies are working on developing unique chemical units and innovative compounds. The global rheumatoid arthritis drugs market is expected to become more competitive as new biologics are developed and a robust clinical pipeline is built. Because of the low entry barriers in the rheumatoid arthritis drugs industry, new market players are expected in the generic pharmaceuticals segment.

• Piroxicam Capsules for the treatment of rheumatoid arthritis and osteoarthritis gained Food and Drug Administration approval from Unichem Laboratories in April 2017.
• In April 2019, Cipla Ltd., bought a 30% share in Brandmed, a South African company, to expand its operations. The acquisition will strengthen Cipla Medpro's portfolio by combining the company's skills with Brandmed's innovative, patient centered health care strategy.

Segments Covered in the Report

By Drug Type

• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
  
  • Ibuprofen
  • Naproxen
  • Diclofenac
  • Indomethacin
• Corticosteroids
  
  • Prednisone
  • Methylprednisolone
  • Dexamethasone
• Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
  
  • Conventional Synthetic DMARDs (csDMARDs)
    
    • Methotrexate
    • Sulfasalazine
    • Leflunomide
    • Hydroxychloroquine
  • Biologic DMARDs (bDMARDs)
    
    • TNF Inhibitors
      
      • Etanercept
      • Infliximab
      • Adalimumab
      • Certolizumab pegol
      • Golimumab
    • Non-TNF Biologics
      
      • Abatacept
      • Rituximab
      • Tocilizumab
      • Sarilumab
  • Targeted Synthetic DMARDs (tsDMARDs)
    
    • Janus Kinase (JAK) Inhibitors
      
      • Tofacitinib
      • Baricitinib
      • Upadacitinib
      • Filgotinib (in some regions)

By Route of Administration

• Oral
• Parenteral
  
  • Intravenous (IV)
  • Subcutaneous (SC)

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Patient Type

• Adult
• Paediatric

By Mode of Purchase

• Prescription-based
• Over the counter

By Geography

• North America
• U.S.
• Canada
• Europe
• U.K.
• Germany
• France
• Asia-Pacific
• China
• India
• Japan
• South Korea
• Malaysia
• Philippines
• Latin America
• Brazil
• Rest of Latin America
• Middle East & Africa (MEA)
• GCC
• North Africa
• South Africa
• Rest of the Middle East & Africa